BDNF and myeloid sarcoma: In a cross-sectional study, B cells collected from patients who had received alemtuzumab secreted significantly higher levels of IL-10 and brain-derived neurotrophic factor (BDNF) up to month 24 compared to a cohort of pre-treated MS patients (50).